NPPB and diabetes mellitus: In the full trial cohort, there was no evidence of heterogeneity of the effect of empagliflozin on systolic BP when subdivided by sex, baseline eGFR, NT-proBNP (Figure 4), or race (Supplemental Figure 4), but there was some evidence to suggest a larger systolic BP difference in patients with diabetes (Figure 4).